These findings suggest that CXCR4/CXCL12 signaling plays an important role in promoting the metastasis of prostate cancer cells to bone, whereas TP53 controls the chemotaxis of cancer cells to the bone marrow endosteal osteoblastic niche by modulating CXCR4 expression. Here, TP53 is linked to cancer.